Clinical Trial: Efficacy and safety of tafasitamab and lenalidomide (TAFA_LEN) in combination with the R-CHOP regimen for the treatment of newly diagnosed intermediate-high-risk diffuse large B-cell lymphoma (China)

Posted On: 2026-10-13

China, Oct. 13 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and safety of tafasitamab and lenalidomide (TAFA_LEN) in combination with the R-CHOP regimen for the treatment of newly diagnosed intermediate-high-risk diffuse large B-cell lymphoma'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600134208

Registration Time: 2026/10/12

Type: Interventional study

Primary Sponsor: The second affiliated hospital of Zhejiang University school of medicine

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=347048

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Efficacy and safety of tafasitamab and lenalidomide (TAFA_LEN) in combination with the R-CHOP regimen for the treatment of newly diagnosed intermediate-high-risk diffuse large B-cell lymphoma (China)